About Abbott Laboratories (NYSE:ABT)
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
Industry, Sector and Symbol
Sub-IndustryHealth Care Equipment
Trailing P/E Ratio57.8557692307692
Forward P/E Ratio21.04
Sales & Book Value
Annual Sales$27.39 billion
Price / Sales3.82
Cash Flow$3.66 per share
Price / Cash16.43
Book Value$12.04 per share
Price / Book5.00
Net Income$477 million
Return on Equity13.80%
Return on Assets6.15%
Abbott Laboratories (NYSE:ABT) Frequently Asked Questions
What is Abbott Laboratories' stock symbol?
Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."
How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?
Abbott Laboratories declared a quarterly dividend on Friday, February 16th. Stockholders of record on Friday, April 13th will be given a dividend of $0.28 per share on Tuesday, May 15th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.86%. The ex-dividend date is Thursday, April 12th. View Abbott Laboratories' Dividend History.
How were Abbott Laboratories' earnings last quarter?
Abbott Laboratories (NYSE:ABT) issued its quarterly earnings data on Wednesday, January, 24th. The healthcare product maker reported $0.74 EPS for the quarter, topping the Zacks' consensus estimate of $0.73 by $0.01. The healthcare product maker had revenue of $7.59 billion for the quarter, compared to analysts' expectations of $7.38 billion. Abbott Laboratories had a return on equity of 13.80% and a net margin of 1.74%. Abbott Laboratories's revenue was up 42.3% on a year-over-year basis. During the same period last year, the company posted $0.65 earnings per share. View Abbott Laboratories' Earnings History.
When will Abbott Laboratories make its next earnings announcement?
What guidance has Abbott Laboratories issued on next quarter's earnings?
Abbott Laboratories updated its FY18 earnings guidance on Wednesday, January, 24th. The company provided earnings per share guidance of $2.80-2.90 for the period, compared to the Thomson Reuters consensus estimate of $2.83. Abbott Laboratories also updated its Q1 guidance to $0.57-0.59 EPS.
Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2018?
18 analysts have issued twelve-month price objectives for Abbott Laboratories' stock. Their predictions range from $45.00 to $80.00. On average, they anticipate Abbott Laboratories' share price to reach $67.00 in the next year. View Analyst Ratings for Abbott Laboratories.
Are investors shorting Abbott Laboratories?
Abbott Laboratories saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 13,229,656 shares, an increase of 36.6% from the January 12th total of 9,685,399 shares. Based on an average daily volume of 8,362,357 shares, the days-to-cover ratio is presently 1.6 days. Currently, 0.8% of the shares of the company are sold short.
Who are some of Abbott Laboratories' key competitors?
Some companies that are related to Abbott Laboratories include Merck & Co., Inc. (MRK), Amgen (AMGN), Bristol-Myers Squibb (BMY), Novo Nordisk A/S (NVO), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly and (LLY), AstraZeneca (AZN), Celgene (CELG), GlaxoSmithKline (GSK), AstraZeneca (AZN), Beximco Pharmaceuticals (BXP), Shire (SHPG), Shire (SHP), Teva Pharmaceutical Industries (TEVA), Valeant Pharmaceuticals Intl (VRX), Catalent (CTLT) and Dr.Reddy's Laboratories (RDY).
Who are Abbott Laboratories' key executives?
Abbott Laboratories' management team includes the folowing people:
- Miles D. White, Chairman of the Board, Chief Executive Officer (Age 62)
- Brian B. Yoor, Chief Financial Officer, Executive Vice President - Finance (Age 47)
- Michael T. Rousseau, President - Cardiovascular and Neuromodulation (Age 61)
- Hubert L. Allen, Executive Vice President, General Counsel, Secretary (Age 51)
- Stephen R. Fussell, Executive Vice President - Human Resources (Age 59)
- Brian J. Blaser, Executive Vice President - Diagnostics Products (Age 52)
- John M. Capek Ph.D., Executive Vice President - Ventures (Age 55)
- Robert B. Ford, Executive Vice President - Medical Devices (Age 43)
- Heather L. Mason, Executive Vice President - Nutritional Products (Age 56)
- Roger M Bird, Senior Vice President - U.S. Nutrition (Age 60)
Who owns Abbott Laboratories stock?
Abbott Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.33%), Bank of New York Mellon Corp (1.80%), Geode Capital Management LLC (1.04%), Macquarie Group Ltd. (0.75%), Alliancebernstein L.P. (0.72%) and TIAA CREF Investment Management LLC (0.62%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.
Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?
Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Flossbach Von Storch AG, Independent Franchise Partners LLP, Rockefeller Financial Services Inc., Teachers Advisors LLC, Eagle Asset Management Inc., Bank of New York Mellon Corp and Macquarie Group Ltd.. Company insiders that have sold Abbott Laboratories company stock in the last year include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert E Funck, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.
Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?
Abbott Laboratories' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Amundi Pioneer Asset Management Inc., Bank of Montreal Can, Redmile Group LLC, Gotham Asset Management LLC, Schwab Charles Investment Management Inc., Geode Capital Management LLC and SG Americas Securities LLC. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.
How do I buy Abbott Laboratories stock?
Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abbott Laboratories' stock price today?
One share of Abbott Laboratories stock can currently be purchased for approximately $60.17.
How big of a company is Abbott Laboratories?
Abbott Laboratories has a market capitalization of $104.73 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $1.04 on an earnings per share basis. Abbott Laboratories employs 75,000 workers across the globe.
How can I contact Abbott Laboratories?
Abbott Laboratories' mailing address is 100 Abbott Park Rd, ABBOTT PARK, IL 60064-3500, United States. The healthcare product maker can be reached via phone at +1-847-9376100.
MarketBeat Community Rating for Abbott Laboratories (ABT)MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Abbott Laboratories (NYSE:ABT) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.78||2.81||2.64||2.69|
|Ratings Breakdown: ||0 Sell Rating(s)|
4 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
3 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
4 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$67.00||$61.27||$57.64||$52.83|
|Price Target Upside: ||6.60% upside||3.30% upside||3.36% upside||6.07% upside|
Abbott Laboratories (NYSE:ABT) Consensus Price Target History
Abbott Laboratories (NYSE:ABT) Analyst Ratings History
(Data available from 2/19/2016 forward)
Abbott Laboratories (NYSE:ABT) Earnings History and Estimates Chart
Abbott Laboratories (NYSE ABT) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|1/24/2018||Q4 2017||$0.73||$0.74||$7.38 billion||$7.59 billion||View||Listen|
|10/18/2017||9/30/2017||$0.65||$0.66||$6.72 billion||$6.83 billion||View||N/A|
|7/20/2017||Q2 2017||$0.60||$0.62||$6.63 billion||$6.64 billion||View||N/A|
|4/19/2017||3/31/2017||$0.43||$0.48||$6.16 billion||$6.34 billion||View||N/A|
|1/25/2017||Q416||$0.64||$0.65||$5.41 billion||$5.33 billion||View||Listen|
|10/19/2016||Q316||$0.58||$0.59||$5.29 billion||$5.30 billion||View||Listen|
|7/20/2016||Q216||$0.53||$0.55||$5.24 billion||$5.30 billion||View||Listen|
|4/20/2016||Q116||$0.39||$0.41||$4.77 billion||$4.90 billion||View||Listen|
|1/28/2016||Q415||$0.61||$0.62||$5.31 billion||$5.20 billion||View||Listen|
|10/21/2015||Q315||$0.53||$0.54||$5.16 billion||$5.15 billion||View||Listen|
|7/22/2015||Q215||$0.50||$0.52||$5.15 billion||$5.20 billion||View||Listen|
|4/22/2015||Q115||$0.42||$0.47||$4.85 billion||$4.90 billion||View||Listen|
|1/29/2015||Q414||$0.68||$0.71||$5.48 billion||$5.36 billion||View||Listen|
|10/22/2014||Q314||$0.60||$0.62||$5.62 billion||$5.10 billion||View||Listen|
|7/16/2014||Q214||$0.51||$0.54||$5.53 billion||$5.55 billion||View||Listen|
|4/16/2014||Q114||$0.36||$0.41||$5.29 billion||$5.24 billion||View||Listen|
|1/22/2014||Q413||$0.58||$0.58||$5.72 billion||$5.66 billion||View||Listen|
|10/16/2013||Q313||$0.52||$0.55||$5.46 billion||$5.37 billion||View||Listen|
|7/17/2013||Q2 2013||$0.44||$0.46||$5.53 billion||$5.45 billion||View||Listen|
|4/17/2013||Q1 2013||$0.41||$0.42||$5.42 billion||$5.38 billion||View||Listen|
|1/23/2013||Q4 2012||$1.50||$1.51||$10.58 billion||$10.80 billion||View||Listen|
Abbott Laboratories (NYSE:ABT) Earnings Estimates
2018 EPS Consensus Estimate: $2.85
2019 EPS Consensus Estimate: $3.17
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Abbott Laboratories (NYSE:ABT) Dividend Information
|Dividend Growth:||6.40% (3 Year Average)|
|Payout Ratio:||107.69% (Trailing 12 Months of Earnings) |
39.16% (Based on This Year's Estimates)
34.89% (Based on Next Year's Estimates)
|Track Record:||45 Years of Consecutive Dividend Growth|
Abbott Laboratories (NYSE:ABT) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Abbott Laboratories (NYSE ABT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.76%
Institutional Ownership Percentage: 70.01%
Abbott Laboratories (NYSE ABT) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/31/2018||Brian J Blaser||Insider||Sell||27,733||$62.26||$1,726,656.58||156,587|| |
|1/30/2018||Stephen R Fussell||EVP||Sell||13,313||$62.84||$836,588.92||152,343|| |
|12/14/2017||Daniel Gesua Sive Salvadori||Insider||Sell||28,319||$54.92||$1,555,279.48||102,117|| |
|12/6/2017||Miles D White||Chairman||Sell||276,886||$54.41||$15,065,367.26||3,677,913|| |
|11/30/2017||Sharon J Bracken||Insider||Sell||2,188||$56.12||$122,790.56||25,618|| |
|11/22/2017||Alejandro D Wellisch||Insider||Sell||2,153||$55.86||$120,266.58||10,256|| |
|11/17/2017||Brian J Blaser||Insider||Sell||23,866||$55.55||$1,325,756.30||146,387|| |
|11/14/2017||Daniel Gesua Sive Salvadori||Insider||Sell||71,157||$55.00||$3,913,635.00||144,955|| |
|10/23/2017||Daniel Gesua Sive Salvadori||EVP||Sell||96,603||$56.21||$5,430,054.63||142,082|| |
|9/26/2017||Daniel Gesua Sive Salvadori||Insider||Sell||62,460||$52.95||$3,307,257.00||113,426|| |
|9/22/2017||Jaime Contreras||Insider||Sell||52,700||$51.97||$2,738,819.00||58,739|| |
|8/16/2017||Stephen R Fussell||Insider||Sell||196,550||$49.50||$9,729,225.00||221,488|| |
|8/1/2017||Sharon J Bracken||Insider||Sell||2,000||$49.16||$98,320.00||28,806|| |
|7/27/2017||Brian J Blaser||Insider||Sell||15,000||$50.00||$750,000.00||143,154|| |
|7/25/2017||Hubert L Allen||Insider||Sell||4,600||$50.79||$233,634.00||105,479|| |
|6/15/2017||Jared Watkin||Insider||Sell||552||$47.97||$26,479.44||47,090|| |
|6/8/2017||Stephen R Fussell||Insider||Sell||196,550||$46.00||$9,041,300.00||221,488|| |
|4/27/2017||Roger Bird||Insider||Sell||5,600||$43.82||$245,392.00||51,313|| |
|4/26/2017||Joseph J Manning||Insider||Sell||4,200||$43.95||$184,590.00||26,224|| |
|3/1/2017||Michael J. Warmuth||Insider||Sell||3,851||$45.39||$174,796.89|| |
|2/23/2017||Robert E Funck||VP||Sell||25,500||$45.50||$1,160,250.00||117,579|| |
|2/22/2017||Roger Bird||Insider||Sell||13,222||$45.02||$595,254.44||63,910|| |
|2/21/2017||Deepak S Nath||Insider||Sell||319||$44.98||$14,348.62||58,471|| |
|1/31/2017||Heather L Mason||Insider||Sell||35,700||$40.77||$1,455,489.00||100,189|| |
|12/20/2016||Brian J Blaser||Insider||Buy||15,580||$38.45||$599,051.00||129,782|| |
|12/14/2016||Robert B Ford||Insider||Buy||12,775||$39.09||$499,374.75||51,532|| |
|11/10/2016||Miles D White||Chairman||Buy||121,456||$40.45||$4,912,895.20||2,802,558|| |
|11/1/2016||Sally E Blount||Director||Buy||5,100||$39.24||$200,124.00||20,143|| |
|9/26/2016||Daniel Gesua Sive Salvadori||SVP||Sell||815||$41.71||$33,993.65||59,791|| |
|7/28/2016||Stephen R Fussell||Insider||Sell||41,500||$45.00||$1,867,500.00||196,467|| |
|7/26/2016||Michael J Warmuth||Insider||Sell||26,800||$43.49||$1,165,532.00||81,811|| |
|7/25/2016||Miles D White||Chairman||Buy||242,547||$43.18||$10,473,179.46||2,010,517|| |
|7/25/2016||Robert E Funck||VP||Sell||26,800||$43.08||$1,154,544.00||111,819|| |
|6/28/2016||Hubert L Allen||EVP||Sell||3,400||$37.14||$126,276.00||91,857|| |
|6/15/2016||Jared Watkin||SVP||Sell||552||$37.63||$20,771.76||47,114|| |
|6/1/2016||Brian B Yoor||CFO||Sell||565||$39.49||$22,311.85||50,182|| |
|4/28/2016||Deepak S Nath||SVP||Sell||53||$41.31||$2,189.43||47,435|| |
|3/31/2016||Jaime Contreras||SVP||Sell||462||$41.78||$19,302.36||47,667|| |
|2/29/2016||Brian B Yoor||CFO||Sell||865||$39.12||$33,838.80||52,250|| |
|2/29/2016||Deepak S Nath||SVP||Sell||793||$39.27||$31,141.11||48,364|| |
|2/29/2016||Robert B Ford||EVP||Sell||1,706||$39.28||$67,011.68||62,495|| |
|2/29/2016||Robert E Funck||VP||Sell||1,333||$39.30||$52,386.90||86,352|| |
|2/22/2016||Jared Watkin||SVP||Sell||554||$39.09||$21,655.86||50,515|| |
|2/16/2016||Deepak S. Nath||SVP||Sell||171||$37.13||$6,349.23||34,941|| |
|12/16/2015||Miles D. White||CEO||Sell||438,000||$46.00||$20,148,000.00||1,394,153|| |
|8/18/2015||Stephen R. Fussell||EVP||Sell||13,096||$50.46||$660,824.16||130,601|| |
|4/27/2015||Heather L Mason||EVP||Sell||13,500||$47.45||$640,575.00|| |
|4/27/2015||Roger Bird||SVP||Sell||28,548||$47.57||$1,358,028.36|| |
|3/26/2015||J. Scott White||SVP||Sell||12,483||$46.68||$582,706.44|| |
|3/2/2015||Jaime Contreras||SVP||Sell||9,209||$47.34||$435,954.06|| |
|2/4/2015||John M Capek||EVP||Sell||34,292||$45.66||$1,565,772.72|| |
|11/25/2014||Jaime Contreras||SVP||Sell||51,600||$44.07||$2,274,012.00|| |
|10/29/2014||Miles D White||CEO||Sell||440,800||$42.52||$18,742,816.00|| |
|3/3/2014||John Landgraf||EVP||Sell||17,293||$39.38||$680,998.34||95,131|| |
|3/3/2014||Katherine Doyle||SVP||Sell||6,639||$39.01||$258,987.39||47,525|| |
|3/3/2014||Robert Funck||VP||Sell||1,413||$38.97||$55,064.61||62,926|| |
|2/18/2014||John Landgraf||EVP||Sell||1,583||$39.10||$61,895.30||102,421|| |
|1/29/2014||Michael Warmuth||EVP||Sell||11,430||$36.21||$413,880.30||40,487|| |
|12/6/2013||Jean-Yves Pavee||SVP||Sell||5,855||$37.46||$219,328.30||30,901|| |
|11/7/2013||Stephen Fussell||EVP||Sell||10,466||$37.59||$393,416.94||101,169|| |
|10/30/2013||Jaime Contreras||SVP||Sell||25,368||$36.85||$934,810.80|| |
|6/7/2013||Heather L Mason||SVP||Sell||12,000||$37.01||$444,120.00|| |
|2/1/2013||William A Osborn||Director||Buy||10,000||$33.86||$338,600.00|| |
Abbott Laboratories (NYSE ABT) News Headlines
Abbott Laboratories (NYSE:ABT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Abbott Laboratories (NYSE:ABT) Income Statement, Balance Sheet and Cash Flow Statement
Abbott Laboratories (NYSE ABT) Stock Chart for Monday, February, 19, 2018